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Cystic  ﬁbrosis  can affect  food  digestion  and  nutrient  absorption.  The  underlying  mutation  of the  cystic
ﬁbrosis  trans-membrane  regulator  gene  depletes  functional  cystic  ﬁbrosis  trans-membrane  regulator  on
the  surface  of  epithelial  cells  lining  the  digestive  tract  and  associated  organs,  where  Cl− secretion  and  sub-
sequently  secretion  of water  and other  ions  are impaired.  This  alters  pH  and  dehydrates  secretions  that
precipitate  and  obstruct  the  lumen,  causing  inﬂammation  and  the  eventual  degradation  of  the  pancreas,
liver,  gallbladder  and intestine.  Associated  conditions  include  exocrine  pancreatic  insufﬁciency,  impaired
bicarbonate  and  bile  acid secretion  and  aberrant  mucus  formation,  commonly  leading  to  maldigestion
and  malabsorption,  particularly  of  fat and  fat-soluble  vitamins.  Pancreatic  enzyme  replacement  therapy
is  used  to address  this  insufﬁciency.  The  susceptibility  of  pancreatic  lipase  to acidic  and enzymatic  inac-
tivation  and decreased  bile  availability  often  impedes  its  efﬁcacy.  Brush  border  digestive  enzyme  activity
and  intestinal  uptake  of  certain  disaccharides  and  amino  acids  await  clariﬁcation.  Other  complications
that  may  contribute  to maldigestion/malabsorption  include  small  intestine  bacterial  overgrowth,  enteric
circular  muscle  dysfunction,  abnormal  intestinal  mucus,  and  intestinal  inﬂammation.  However,  there  is
some  evidence  that gastric  digestive  enzymes,  colonic  microﬂora,  correction  of fatty  acid  abnormalities
using  dietary  n  −  3 polyunsaturated  fatty  acid  supplementation  and  emerging  intestinal  biomarkers  can
complement  nutrition  management  in  cystic  ﬁbrosis.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by  Elsevier  Ltd.  
D lice. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive condition caused by
utations of the cystic ﬁbrosis trans-membrane regulator (CFTR)
ene. The consequence is a deﬁciency or absence of functional
FTR proteins on the apical membrane of secretory and absorp-
ive epithelial cells in multiple organs throughout the digestive
ystem [1]. The absence of functional CFTR proteins disables the
rans-epithelial movement of Cl− ions through CFTR-associated Cl−
hannels, which normally drives the secretion of ﬂuid and other
ons [2]. Dehydration of various secretions (e.g. mucus) at affected
Open access under CC BY-NC-Nites thus occurs, resulting in the precipitation of secretions and
ntra-ductal blockage, inﬂammation, ﬁbrosis and eventual damage
o the organs, particularly in the presence of digestive enzymes
∗ Corresponding author at: School of Allied Health, Faculty of Health Sciences, Aus-
ralian Catholic University, Brisbane, 1100 Nudgee Road, Banyo, Queensland 4014,
ustralia. Tel.: +61 7 3623 7183.
E-mail  addresses: li.li14@grifﬁthuni.edu.au (L. Li), shawn.somerset@acu.edu.au
S.  Somerset).
ttp://dx.doi.org/10.1016/j.dld.2014.06.011
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Op[3]. Although the exact manifestation is site-speciﬁc, the common
pathophysiology is described above.
Numerous studies on single or multiple challenges in the diges-
tive system in CF have been published. This review aims to integrate
the manifestations and complications of CF throughout the entire
digestive system and the changes in the digestion of food and
absorption of nutrients to highlight the potential impact on nutrient
acquisition and nutritional status in CF.
2. Factors inﬂuencing digestion and absorption
2.1. Pancreatic manifestations of CF and lipid maldigestion and
malabsorption
Despite  its exo-gastrointestinal anatomical location, the pan-
creas is the major organ responsible for the digestion of
carbohydrate, protein and lipid through the secretion of various
nse.digestive enzymes into the duodenum [4]. These enzymes mainly
include pancreatic amylase, protease, lipase and colipase. Pancre-
atic acinar cells secrete inactive pancreatic digestive enzymes into
the acinar lumen, which extends to the pancreatic ducts [3,5].
en access under CC BY-NC-ND license.
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he ducts consist of ductal cells that produce bicarbonate (HCO3−)
nduced by cAMP to alkalinise and dilute the acinar secretions and
eutralise gastric acid in the duodenal lumen [6,7].
Cystic ﬁbrosis trans-membrane regulator is normally highly
xpressed in the pancreas, particularly in the small intercalated
ucts that connect the acini [7]. Deﬁciency of functional CFTR in
F thus leads to decreased ductal cell secretions of Cl−, water and
CO3−, which also lowers pH [3,5]. The concentrated secretions
ause dilation and obstruction of the ducts, particularly in the pres-
nce of macromolecules [3] such as inactive digestive enzymes.
igestion and neutralisation of the acidic duodenal content is hin-
ered by suppressed secretion of pancreatic digestive enzymes
nd HCO3−. The lower ductal pH can also damage the pancre-
tic epithelium [4,8]. The inactive form of trypsin (trypsinogen)
emains inactive only in the normal alkaline milieu of the pancre-
tic duct. Ductal secretion of HCO3− is diminished in the presence
f trypsin [8]. Irreversible damage to the acinar cells and ﬁbrosis
rising from luminal obstruction and premature activation of pan-
reatic protease due to lowered pH further reduces the synthesis
nd exocytosis of pancreatic digestive enzymes and HCO3− [9]. The
esultant exocrine pancreatic insufﬁciency (PI) is the leading cause
f maldigestion and malabsorption in CF (Fig. 1) [10]. Clinical man-
festation of PI occurs when less than 5–10% of the normal prandial
nzymes are produced [4,9,10]. A compensatory release of pan-
reatic enzyme in response to nutrients (particularly undigested
riglycerides) can occur in moderate PI [10]. However, the preva-
ence of PI in CF still approximates 85–90% worldwide, an incidence
hat increases with age [3,5,11–13].
Other factors contributing to PI have also been reported (Fig. 1).
orrelation with the F508 mutation of CFTR is very strong [5].
mbalance of membrane phospholipids in pancreatic cells may  also
ontribute to pathogenesis [5]. Murine models of CF have demon-
trated elevated membrane-bound arachidonic acid (AA) levels in
ancreas compared with controls [14,15]. The level of membrane-
ound docosahexaenoic acid (DHA) may  be either elevated or
naltered. Excessive incorporation of AA instead of DHA into mem-
rane phospholipids can inﬂuence membrane ﬂuidity and thereby
ermeability to ions such as Cl− and HCO3− and water [5]. Reduced
roduction of DHA and enhanced synthesis of docosapentaenoate,
he precursor of DHA, has been observed in total pancreatic phos-
holipids in a CFTR-knockout murine model [16]. Abnormal proﬁles
f essential fatty acids (EFA) have been indicated in CF human
issues and plasma [15,17]. However, the relevance of investiga-
ions to date remains uncertain since fatty acid proﬁles can vary
etween different phospholipid species related to speciﬁc mem-
rane domains [16,18]. Also, the activity of 5 desaturase, critical
n AA synthesis, is higher in murine than in human models [18].
enetic background, diet, age and gender of CF murine models may
lso inﬂuence EFA status in tissues, including the pancreas [17,19].
hus, the relationship between membrane phospholipid and PI [5]
eeds further investigation.
The  impact of PI on digestion and absorption varies according to
acronutrient [4]. Individuals with chronic pancreatitis (and con-
equent diminished pancreatic enzyme output) can absorb around
0% of a carbohydrate load compared with 80% in healthy partic-
pants with deactivated amylase [4], implying that carbohydrate
igestion and absorption reach reasonable levels in CF with PI [4].
owever, since products of microbial fermentation of carbohy-
rate exert higher osmotic pressure, symptoms such as abdominal
istension, ﬂatulence and diarrhoea may  present because of an
verload of undigested carbohydrate, along with changes in nutri-
ional status [4]. Protein digestion also appears to be moderately
ompensated for, in both a porcine model and in humans with
I [4]. In contrast, lipid digestion is signiﬁcantly impaired in CF
ith PI, causing steatorrhoea in untreated patients. This latter
ssue is attributable to the susceptibility of pancreatic lipase tor Disease 46 (2014) 865–874
low  pH, low bile acid content and proteolysis by pancreatic chy-
motrypsin [5,10,20]. Moreover, gastric lipase seems to only be
capable of liberating 10–30% of fatty acids from fat emulsions [4].
Thus, maldigestion and malabsorption occur mainly with dietary
lipids and hence fat-soluble vitamins in the majority of individuals
with CF if untreated. It is therefore common practice to supplement
individuals with CF and PI with exogenous pancreatic enzymes,
which is called pancreatic enzyme replacement therapy (PERT), and
the dosage is matched with the fat content of meals or enteral feeds
rather than protein or carbohydrate [9,12,21–23].
2.2. Factors affecting PERT efﬁcacy
The goal of PERT is to compensate for maldigestion and mal-
absorption of nutrients in the duodenum by sufﬁcient delivery of
active pancreatic enzymes into the duodenum with ingested food
[21]. Despite the large range of treatment options available [24],
clinical outcomes of PERT may  be compromised [12] owing to fac-
tors such as release of enzymes from their acid-resistant enteric
coating not coinciding with the arrival of chyme in the small intes-
tine (SI) [9]. Compositional variations in enzyme preparation and
coating, the size of enzyme particles, GI transit, and the ratio of
enzyme to dietary fat content can all contribute [9,10,12]. Other
factors include hyperacidity in the stomach/SI and abnormal GI
motility (Fig. 1).
At  a pH below 6.0, PERT enzymes remain inactive owing to the
acid-resistant coating that prevents the enzymes from denatur-
ation [25]. Gastric and SI pH is thus critical in the timing and location
of enzyme release [25]. The impact of CF on gastric pH remains
unclear. A range of characteristics have been observed, including
elevated basal and/or secretagogue-induced gastric acid secretion
[26] and pre- and postprandial [25], as well as interdigestive gas-
tric, pH [27], similar to the healthy controls. Severity of pulmonary
disease or steatorrhoea and level of acid secretion seem not to be
correlated [26]. The weight status of CF patients may account for
some of this uncertainty, since the acid secretion level is calculated
relative to the body weight [25]. Similarly, the role of CFTR in gastric
acid secretion is not entirely clear. Secretagogue-induced gastric
acid secretion in CF murine models can be considerably depressed
by CFTR-speciﬁc inhibitors [28,29], implying that CFTR channels
play a role in gastric acid secretion by interfering with other ion
channels or transporters [28]. This parallels the early observation
that the CFTR expression along the GI tract in adult humans was
low throughout the gastric mucosa, including parietal cells [7].
Therefore, CFTR may  not be the dominant Cl− channel involved in
gastric acid secretion, although its regulatory role in gastric secre-
tion cannot be ignored. In addition, gastric secretion of HCO3−,
which might affect gastric pH, has rarely been investigated. A single
study reported gastric HCO3− secretion in CF comparable to healthy
controls [27]. Thus, gastric pH may  be normal and may  not affect
PERT enzyme release in the SI. However, further investigations to
conﬁrm gastric pH status and clarify the role of CFTR in gastric acid
secretion in CF may  further help to improve the efﬁcacy of PERT.
Indeed, increasing the pH in the proximal SI by either suppressing
gastric acid secretion or administering HCO3− with PERT has been
indicated in some studies to improve PERT efﬁcacy [21,30–33].
Hyperacidity in the SI may  relate to diminished HCO3− secretion
from intestinal mucosa, pancreas, liver and gallbladder where func-
tional CFTRs are absent. The emptying of gastric contents into the
duodenum [34] stimulates HCO3− secretion from duodenal sub-
mucosal (Brunner’s) glands, the intestinal crypt epithelium and
the ductal systems of the liver and pancreas [35]. The alkaline
HCO3− rich secretions neutralise the acidic chyme in the duode-
num [34]. Accumulating evidence suggests that CFTR is involved
in Cl−/HCO3− exchange and hence HCO3− secretion in the duode-
num [36,37], pancreas [5,6] and liver [38]. This is also supported by
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brosis  trans-membrane regulator; PERT: pancreatic enzyme replacement therapy
he distribution of CFTR throughout the digestive system revealed
n rat and human intestinal biopsies [7,39]. Relevant locations
nclude duodenal Brunner’s glands, crypt cells, ductal cells in the
ancreas and liver, and epithelial cells along gallbladder lumen
hat secrete HCO3−. Consequently, in CF where functional CFTR is
bsent, HCO3− content in the duodenum is diminished and may
ail to neutralise the acidic gastric content [40,41]. This is thought
o account for lower pH in the CF duodenum compared with that
f healthy controls [42,43]. In the liver and gallbladder, HCO3− and
uid are either secreted through or mediated by CFTR to alkalinise
nd hydrate bile [7,38,44]. This modiﬁcation of bile is impeded inatic enzyme replacement therapy and lipid digestion and absorption. CFTR: cystic
ocrine pancreatic insufﬁciency; SI: small intestine.
CF, possibly mediated by ATP, which is normally regulated by func-
tional CFTR [38,44,45]. Subsequently, the volume and pH of bile
ﬂow is reduced, adding to duodenal hyperacidity. Indeed, basal
duodenal pH in CF is approximately 5.0 (cf. 6.0 in healthy controls)
[25]. The difference is even greater postprandially (mean pH 3.6, cf.
5–7).
Hyperacidity in the duodenum hinders PERT efﬁcacy by imped-
ing the release and/or activity of pancreatic enzymes [42]. The
enteric coating allows the enzyme release at pH > 5.0 [9,25,46].
The low duodenal pH is likely to hamper the dissolution of the
acid-resistant coating and consequently postpone or even inhibit
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he enzyme release until chyme has passed the major absorp-
ion sites in the duodenum and jejunum [42,46]. The acidic milieu
lso markedly reduces PERT activity (optimal pH range of 7–9)
9,47–49]. Consequently, the low pH in the CF duodenum reduces
he therapeutic value of PERT in correcting maldigestion and mal-
bsorption.
The pH status and hence the action of PERT in the CF jejunum is
ess clear. Although normal jejunal pH values (5.5–6.5) have been
bserved, pH values <5 have also been reported [25,50], indicat-
ng that PERT efﬁcacy may  be compromised in some cases despite
elatively normal jejunal CFTR expression in CF [7].
In  the ileum, pH status may  be unaltered in CF [25,50], but its
nﬂuence on PERT efﬁcacy remains unclear. Ileal CFTR expression
atterns resemble the duodenum and jejunum, apart from lack-
ng the isolated distribution of cells with high CFTR expression [7].
owever, its relevance to ileal pH status in CF awaits investiga-
ion. A mean pH of 7.23 in the CF terminal ileum has been reported
25,50], within the optimal pH range for PERT enzyme release and
ctivation. Such CF ileal pH status may  be explained in vitro where
CO3− secretion appears to be mediated by Cl−/HCO3− exchang-
rs, in addition to CFTR [51]. However, the inﬂuence of the ileal pH
tatus on PERT efﬁcacy as well as digestion and absorption in CF
equires evaluation.
Gastrointestinal motility may  also be altered in CF, affecting
ERT efﬁcacy [42]. Investigations into the fasting motility of the
pper GI tact in CF have shown variable results [27,52]. The post-
randial gastric emptying rate may  be either increased [53,54]
r impaired in CF [52,55]. One study observed delayed gastric
mptying in one third of the adults with CF [55]. These various
isparities may  be due to methodological variations. For example,
ncreased gastric emptying rates were detected in studies employ-
ng scintigraphy [53,54], whereas decreased rates were observed in
tudies using other measuring approaches [52,55]. The macronu-
rient content of a meal, in particular fat content, can also modulate
astrointestinal motor function including gastric emptying [56].
owever, the caloric and macronutrient contents of test meals were
ften not speciﬁed in these studies. Delayed gastric emptying may
orrelate with high oesophageal total bile exposure [55], which can
ccur in CF [57]. Gastric motility may  also be inﬂuenced by total gas-
ric secretion, which can be reduced in CF [27,58], thus increasing
iscosity and electrolyte concentrations [58]. The increased viscos-
ty of CF gastric mucin arises from augmented levels of covalently
ound and associated fatty acids [59]. The viscosity of the total
astric content can change gastric motility and the emptying rate,
hich inﬂuences the delivery of PERT and hence nutrient digestion
nd absorption in CF with PI [42]. Thus, altered gastric motility,
ombined with hyperacidity determines the PERT efﬁcacy. This in
urn has important consequences for digestion and absorption in
F, particularly fat and fat-soluble vitamins.
.3. Other factors inﬂuencing lipid digestion and absorption
Hyperacidity in the CF duodenum may  exacerbate pancreatic
nﬂammation [35] and hence PI. Duodenal hyperacidity causes
xcessive pancreatic HCO3− secretion in CFTR knockout mice, lead-
ng to up-regulation of pancreatic stress and inﬂammation genes
35]. CFTR expression in the proximal intestine is higher in murine
han in rat or human models [60], while the opposite is seen in the
ancreas [7,35]. Thus, whether duodenal hyperacidity aggravates
ancreatic inﬂammation and contributes to PI in human CF needs
lariﬁcation.
Hyperacidity in the CF duodenum may  also precipitate bile [61].
his can impede micelle formation, and therefore lipid absorption
y intestinal mucosa [62], when duodenal bile acid concentration
rops below the critical micelle concentration [61]. Bile salt pre-
ipitation may  also reduce the total bile pool [61] when the liverr Disease 46 (2014) 865–874
is  unable to fully compensate for excessive loss via enterohepatic
circulation [62]. This loss is worsened when unabsorbed protein
and neutral lipids bind to bile salts. Consequently, maldigestion
and malabsorption of lipids is exacerbated by the hyperacidity in
CF duodenum and by the lack of lipases due to PI (Fig. 1).
Lipid  digestion and absorption in CF can be hindered by reduced
bile acid resorption (Fig. 1). As the primary site for bile salt resorp-
tion, the terminal ileum has a highly efﬁcient active Na-bile salt
co-transport system [62]. The daily synthesis rate of bile salt is
0.2–0.4 g. Therefore, any chronic loss exceeding this amount can
deplete the bile salt pool, impeding micelle formation and sub-
stantially contributing to fat maldigestion and malabsorption [63]
irrespective of exocrine pancreatic function. Up  to 50% of dietary
fat can be lost in faeces in the absence of bile. In CF, reduced bile
acid absorption is common. The cause appears to be multifacto-
rial, including a primary defect in the CF ileal mucosa [64] and
enhanced micelle formation owing to the presence of certain undi-
gested and unabsorbed lipids in the ileum [65]. One study in adults
with CF, however, excluded the role of intraluminal fat, together
with small bowel bacterial overgrowth [66]. Correlations between
bile acid excretion (and hence bile salt resorption) and faecal fat
content (representing luminal fat content) as well as hydrogen
breath excretion (indicating small bowel bacterial growth) have not
been observed. Instead, mucosal defects due to thickened mucus
and a negative regulatory role of CFTR in ileal bile acid resorption
have been proposed [67]. Mucosal damage secondary to ageing may
suppress bile acid uptake [63]. Although infants with CF have sim-
ilar bile acid absorption rates to non-CF infants, the older age of
the controls may  have inﬂuenced the results, since animal models
imply that uptake of bile acid increases with age during infancy
[63]. Despite the unconﬁrmed mechanism, bile acid absorption in
CF seems to be impaired in the ileum, where most bile acid should
be reabsorbed and recycled to the bile salt pool. Increased faecal
bile salt loss has also been ascribed to the lowered pH of bile ﬂow
due to decreased HCO3− secretion [45]. However, faecal bile loss
may not be associated with fat malabsorption in CF murine mod-
els [68]. To what degree impaired absorption and increased loss of
bile in CF have an impact on lipid digestion in humans with CF thus
requires further investigation.
Another  factor that can contribute to lipid malabsorption in
CF is the impaired intra-enterocyte processing of lipids (Fig. 1)
[69]. CF duodenal biopsies have shown grossly decreased esteriﬁ-
cation and secretion of lipids and signiﬁcant reductions of lipid and
apolipoprotein synthesis, despite normal transfer protein activ-
ity levels. This implies that altered intra-enterocyte processing
of lipids may  partly account for persistent fat malabsorption in
individuals with CF on PERT in the duodenum. It remains unclear
whether this is also the case in the lower intestine.
2.4. Factors inﬂuencing digestion and absorption of other
nutrients
In  the duodenum, the products of the pancreatic breakdown of
proteins and carbohydrates are further hydrolysed into monomers
by intestinal brush border glycosidases [34] and peptidases, and
by intracellular mucosal cell peptidases [62,70]. This process of
terminal digestion occurs all along the SI, but the duodenum and
jejunum are the major sites for digestion and absorption. The ileum
plays a major role in the terminal digestion of oligosaccharides and
peptides, reﬂected by the high distribution of maltase and some
peptidases [71–73]. The brush border digestive enzymes appear to
be distributed unevenly along the SI segments [72,73].Although carbohydrate and protein digestion and absorption
seem to be less affected in CF, some evidence indicates alterations
to brush border digestive enzyme activity and the uptake of ﬁnal
digestion products (Fig. 2). In CF, the activity of these brush border
L. Li, S. Somerset / Digestive and Live
Fig. 2. Schematic representation of factors inﬂuencing digestion and absorption of
nutrients other than fat and fat-soluble vitamins. AP: alkaline phosphatase; CFTR:
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igestive enzymes varies according to speciﬁc enzymes [74–77].
altase and sucrase activity in CF seem unaffected [77], but lac-
ase activity can be lower in CF mucosa [74,76,77]. The quantity of
actase in CF may  also be suppressed, depending on the genotype
78]. On the other hand, the higher frequency of genetic predis-
osition of lactase suppression among homozygous F508 may
arrant the monitoring of lactose intolerance in this group. The
ossibility of lactase deﬁciency secondary to mucosal damage in
F, as occurs in coeliac disease, and the inﬂuence of CFTR on lac-
ase gene expression still awaits conﬁrmation. Lactose intolerance
s an independent risk factor for low bone mineral density (BMD) in
hildren with CF [79]. Clinical symptoms such as ﬂatulence, abdom-
nal pain and diarrhoea correlate with reduced calcium intake and
MD  [80], contributing to impaired bone health in CF [81]. A better
nderstanding of the dynamics of lactase activity in CF will assist
n addressing bone health issues in this condition.
Reduced peptide hydrolysis activity and intestinal uptake of
ome amino acids have been reported in jejunal biopsies from chil-
ren with CF [76]. Although CFTR expression is high in isolated
ucosal cells throughout the crypts and villi [7,39], it is unclear
hether functional CFTR absence affects bush border enzyme
ecretions. A better understanding of SI brush border digestive
nzyme activity in CF will potentially inform clinical recommen-
ations on the speciﬁc types of carbohydrates and proteins that are
ffected in CF.r Disease 46 (2014) 865–874 869
Absorption of some amino acids may  be altered in CF. Although
glucose uptake may  be enhanced, due to either a decreased per-
fusion barrier secondary to abnormal mucus [82] or enhanced
Na-coupled nutrient transport from increased mucosal membrane
potential due to defective Cl− transport [83], this seems not to be
the case for amino acids. Some studies found enhanced uptake
of amino acids, while others observed reduced or normal uptake
[83], particularly of neutral amino acids and dipeptides respectively
[84]. The exact nutritional consequence of such malabsorption is
unclear. However, signiﬁcantly increased faecal nitrogen loss in CF
children and young adults, partially attributed to excessive faecal
amino acid loss, has been documented [85,86]. A CF murine model
has highlighted that genetic factors other than CFTR mutations may
have an impact upon nutrient absorption in the CF jejunum [87].
Further investigation into the absorption of amino acids and dipep-
tides in humans with CF is required.
Adding to macronutrient and fat-soluble vitamins, vitamin B12
and calcium acquisition may  also be impeded in CF. Parietal cells
secrete intrinsic factor (IF), which mediates the digestive trans-
port and absorption of vitamin B12 [88]. Elevated secretion of IF
upon stimulation by pentagastrin was reported in a small study
of children with CF [89]. Unaltered biological activity of IF was
observed in another paediatric CF group, but the carbohydrate
composition of IF appeared altered [90]. However, food-derived
B12 assimilation is probably not greatly affected in CF [89], with
only occasional reports of vitamin B12 deﬁciency [91]. In contrast
to observations in humans, decreased absorption of vitamin B12
has been demonstrated in CF murine models, in which the gene
coded for the endocytic receptor for absorption of the IF–vitamin
B12 complex was down-regulated [92]. The extent of the impact
of CF on vitamin B12 assimilation in humans requires clariﬁcation.
Meanwhile, reduced activity of brush border alkaline phosphatase
[93], which suppresses intestinal calcium uptake induced by high
luminal calcium concentrations [94], may  be related to calcium
absorption and bone health in CF, in addition to potential lactose
intolerance. Further research is required to assess its inﬂuence on
calcium absorption, since bone disease has emerged as a common
comorbidity with increasing life expectancy in the CF population
[95].
2.5. Other contributors of maldigestion and malabsorption
Other complications in the CF small intestine that may  con-
tribute to maldigestion and malabsorption include small intestine
bacterial overgrowth (SIBO), enteric circular muscle dysfunction,
abnormal intestinal mucus, SI inﬂammation and decreased gas-
trointestinal transit time (Fig. 3). Prevalence of SIBO based on breath
test results is 30–50% among CF patients [96]. Bacterial overgrowth
can compete for ingested nutrients, interfering with digestion and
absorption. Certain bacteria such as Clostridium perfringens produce
hydrolases that can deactivate bile acids [97], leading to impaired
micelle formation and consequently impaired lipid digestion and
absorption. Approximately 6% of the bacterial overgrowth in the SI
of a CF knockout murine model consists of C. perfringens [98]. Sig-
niﬁcant weight gain has been observed in CF mice whose SIBO was
eliminated using antibiotics, implying that SIBO might impair nutri-
ent acquisition in CF. Delayed SI transit may  impede digestion and
absorption in CF indirectly by disrupting the interdigestive migrat-
ing motor complex, which helps to minimise the bacterial load in
the SI between meals [99]. Dysfunctional circular smooth muscle
has been observed in CF murine SI [100]. This dysfunction relates
to prostaglandin levels modulated by intestinal bacteria such asmicrobiota of SIBO. Prolonged SI transit may  also be caused by undi-
gested lipid due to insufﬁcient active forms of bile acids, leading to
activation of the ileal brake, which slows SI transit [96]. Distribution
870 L. Li, S. Somerset / Digestive and Liver Disease 46 (2014) 865–874
Fig. 3. Schematic representation of other factors inﬂuencing digestion and absorp-
t
i
a
i
a
t
f
m
d
C
i
[
C
i
t
o
d
h
s
t
a
w
d
i
g
c
s
m
enzymes are similar to, if not higher than, normal adult referencesion in cystic ﬁbrosis. CFTR: cystic ﬁbrosis trans-membrane regulator; SI: small
ntestine; SIBO: small intestinal bacteria overgrowth.
nd components of enterocytes with notably high CFTR expression
n the rodent SI implies an important role for these cells in clearing
dherent mucus from the epithelium for effective nutrient absorp-
ion by the secretion of a high volume of ﬂuid [101]. Thus, fat and
at-soluble vitamin absorption may  be distorted by abnormal SI
ucosa [42], since the diffusion of micelles across the thickened,
ehydrated unstirred water layer may  be less efﬁcient [11]. Murine
F models have also demonstrated weakly acidic and sulphated
ntestinal mucus that may  alter SI function and nutrient diffusion
42]. Low grade SI inﬂammation, found in both murine and human
F models [42,92,102], may  also impede mucosal function, further
mpairing fat and, possibly, vitamin B12, absorption [11]. In addi-
ion, accelerated gastrointestinal transit due to aberrant enzyme
utput in CF with PI, independent of PI aetiology, may  also impede
igestion and absorption [9].
Throughout the process of digestion and absorption, carbo-
ydrates and proteins are digested by enzymes secreted by the
alivary, gastric, pancreatic and intestinal glands. Therefore, pro-
ein and carbohydrate digestion is substantially maintained in the
bsence of pancreatic proteases and amylase and thereby in CF
ith PI [10]. Conversely, the major enzymes responsible for lipid
igestion are secreted by the pancreas. Decreased pH secondary to
mpaired HCO3− secretion by the pancreas, duodenum, liver and
allbladder due to defective or absent CFTR can affect PERT efﬁ-
acy, despite adjunct therapy. This is likely exacerbated by the
usceptibility of pancreatic lipase to proteolysis. Consequently,
aldigestion and malabsorption, particularly of dietary fat andFig. 4. Potential enhancers of and associated barriers to nutrition therapy. MCFA:
medium  chain fatty acid; SCFA: short chain fatty acid; PERT: pancreatic enzyme
replacement  therapy.
fat-soluble vitamins, is common and remains a priority for nutrition
therapy in CF [68].
3.  Potential enhancers of nutrient and energy acquisition
While  CF manifestations and complications in the digestive sys-
tem can impede nutrient acquisition, other aspects of the digestive
system in CF may  potentially enhance energy and nutrient acqui-
sition (Fig. 4).
Salivary  amylase and gastric lipase and pepsin may compen-
sate for the maldigestion and malabsorption in CF due to PI. Similar
salivary amylase activity levels have been found in CF children and
controls [103]. Several small studies have highlighted the poten-
tial value of lingual lipase for lipid digestion in CF [104–106].
Subsequently, gastric lipase was found to account for almost all
pre-duodenal lipase activity in humans, with limited lingual lipase
contribution [107]. Indeed, studies on gastric lipase and protease
have reported more promising ﬁndings. Gastric lipase and protease
(pepsin) are secreted by chief cells in the stomach [34,108], which
also express CFTR [7]. Intriguingly, one paediatric CF study showed
that the basal and postprandial output and activity of these two[109]. These results are likely to be relevant to adults with CF, since
CFTR functions in foetal and adult digestive tracts are compara-
ble, unlike those in the respiratory system [7]. In addition, gastric
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ipase, with an optimal pH of 5.4 [110], seems to have a higher
ctivity in the acidic CF duodenum [111], in contrast to PERT lipase.
hus, the acidic duodenal environment may  extend the activity
f gastric lipase and partially compensate for fat maldigestion in
I. These two enzymes may  partially alleviate maldigestion and
alabsorption due to PI in CF [108,111]. Notably, gastric lipase
ccounts for up to 90% of total postprandial lipase activity in the
pper small intestine in patients with CF and PI [109]. Despite this,
xogenous enzyme supplementation still seems necessary, partic-
larly for the high fat diet commonly recommended for individuals
ith CF and PI [112]. This is because the output and activity levels
f gastric lipase and pepsin in participants with CF do not seem
o increase with dietary fat content [109]. Moreover, most stud-
es investigating the efﬁcacy of gastric lipase in CF engaged only
mall samples and are somewhat dated. Even fewer studies have
xamined the efﬁcacy of pepsin in CF. Further studies with larger
amples are needed to evaluate the potential therapeutic value of
hese enzymes to complement PERT, which has shown variable
fﬁcacy in CF [68,112].
Apart  from PERT usage, the large intestine and its microbiota
ay offer the potential to increase energy harvest in CF [113].
nly small amounts of the nutrients not absorbed in the upper
I tract can be salvaged by the colonocytes alone [34]. These are
ainly water and electrolytes, the majority of which have already
een absorbed in the jejunum and proximal ileum [11]. How-
ver, CF murine models have demonstrated that medium chain
atty acids, C18 in particular, can also be absorbed in the colon
114,115]. Microbial metabolites of nutrients that have escaped
bsorption in the upper GI tract (e.g. short chain fatty acids [SCFA])
re also absorbed here [34]. In humans with intestines of normal
ength and function, approximately 5–10% of energy requirements
re derived from the colonic microbial fermentation of undigested
nd/or unabsorbed food components [116]. In patients with sub-
tantial intestinal resection, colonic fermentation can provide up
o 1000 kcal/day [117]. Absorption of SCFAs may  be enhanced in
F [118], although major SCFA species can stimulate glucagon-like
eptide 1 production [119] and intestinal gluconeogenesis [120]
ssociated with reduced weight and adiposity. Further research
s warranted to evaluate the therapeutic potential of the colonic
icrobiota in rescuing energy lost in the upper GI tract due to PI
nd other GI manifestations of CF.
Abnormal colonic mucosa may  also have an impact upon energy
arvest in CF. Increased accumulation of insoluble mucus in the CF
olon, together with other abnormalities in mucus quantity and
hickness [121] may  relate to abnormal transport of Na+ and possi-
ly HCO3−. Since normal mucins trap and bind bacteria [121], such
ucosal abnormalities may  affect the energy harvest from SCFA
nd potentially energy compensation by gut bacteria in CF. Fur-
hermore, the microbiota may  be altered in inﬂammatory bowel
isease, particularly Crohn’s disease [122]. A CF knockout murine
odel has indicated altered expression of genetic factors involved
n the development of colitis or Crohn’s disease [123]. In CF, altered
ut microbiota has also been reported [124–126]. The extent to
hich bowel inﬂammation can affect the gut microbial community
nd its capacity to rescue energy in health and CF await inves-
igation. The extent of the inﬂuence of mucus abnormalities on
otential colonic energy harvest in CF is undetermined and the
herapeutic value of colonic energy harvested from SCFA also needs
urther analysis. A CFTR-knockout murine model has also implied
he potential absorption capacity of fat soluble vitamin E in the CF
olon [115]. This requires investigation so that supplementation
egimens for fat-soluble vitamins including vitamin E in CF can be
ptimised.
Alleviation of an abnormal EFA proﬁle using n-3 polyunsat-
rated fatty acid (PUFA) supplementation may  also potentially
mprove digestion and contribute to nutritional management inr Disease 46 (2014) 865–874 871
CF owing to its anti-inﬂammatory [127] and anti-bacterial effect
[128]. Although publications on the efﬁcacy of dietary n − 3 PUFA
supplementation in improving digestive functions (including the
pancreas and intestine) in CF are lacking, improved EFA proﬁles in
the CF intestine [129,130] and blood (serum and red blood cells)
[129–132] in vivo and in the respiratory tract in vitro [133,134]
post-supplementation have been reported. Despite controversies
[129,130,132], improved lung function, inﬂammatory markers and
nutritional status have been reported after one-year oral supple-
mentation of mixed n − 3 PUFA [131]. However, the different
supplementation regimes and study designs have not allowed the
Cochrane Systematic Review to conﬁrm the efﬁcacy of n − 3 PUFA
supplementation in CF management [127]. In fact, the inﬂuence
of dysfunctional digestion and absorption in CF on the uptake of
n − 3 PUFA has not been reported. The efﬁcacy and effectiveness of
such dietary supplementation in improving the digestive function
in CF require evaluation, as abnormal EFA metabolism in CF may
be indirectly linked to dysfunctional CFTR by activation of a pro-
tein kinase-regulating lipid metabolism via abnormal cellular Ca2+
metabolism [135].
Interestingly, abnormalities in the CF intestine may  serve as
biomarkers to complement CF diagnosis, particularly in cases of
‘non-classic CF’, and/or indicate clinical outcomes for trials of CF
therapeutics [136], thus paving the way for more efﬁcient CF man-
agement including digestive health. Examples are the intestinal
current measurement [137,138] and faecal fat tests [139]. Protein
biomarkers constitute another such group, which can potentially
be identiﬁed using various proteomic techniques [140] adapted for
use in the CF context [136]. Faecal calprotectin is such an example,
which can be used to indicate intestinal inﬂammation [124].
4.  Conclusion
In summary, it seems that a variety of manifestations of CF and
associated complications contribute to maldigestion and malab-
sorption, affecting nutritional status in the long-term. Acquisition
of fat and fat-soluble vitamins remains the major nutritional chal-
lenge in CF owing to the susceptibility of pancreatic enzymes and
variable efﬁcacy of PERT in individuals with CF and PI. Nutritional
status of vitamin B12 and calcium also requires regular monitor-
ing for individuals with speciﬁc GI complications. Gastric digestive
enzymes and gut microbial bacteria may  have the therapeutic
potential to complement current PERT and dietary therapies to
improve nutritional status and hence survival in CF. Correction of
EFA abnormalities in the CF digestive system using dietary n − 3
PUFA supplementation has shown some promise, and the use
of intestinal biomarkers has shown potential in the diagnosis of
CF and/or evaluation of CF therapeutics. Future investigation is
required to evaluate the feasibility and efﬁcacy of these approaches
to further improve CF management.
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